NASDAQ:ZBIO Zenas BioPharma Q3 2026 Earnings Results & Report $28.46 +0.08 (+0.28%) Closing price 11/4/2026 04:00 PM EasternExtended Trading$28.46 0.00 (0.00%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Zenas BioPharma missed analyst earnings expectations in its Q3 2026 results, released November 5, 2026. The company reported EPS of -$1.65 versus the -$1.20 consensus estimate, while revenue was $10 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 5, 2026TimeBefore Market OpensConference Call7:00 AM ET Zenas BioPharma EPS ResultsActual EPS-$1.65Consensus EPS -$1.20Beat/MissMissed by -$0.45One Year Ago EPSN/AEPS Beat Rate2 of last 7 quartersZenas BioPharma Revenue ResultsActual Revenue$10 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsZenas BioPharma's Q4 2026 earnings is estimated for Wednesday, November 18, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Zenas BioPharma Q3 2026 Earnings FAQ Did Zenas BioPharma beat earnings estimates for Q3 2026? Zenas BioPharma (NASDAQ:ZBIO) reported earnings of -$1.65 per share for Q3 2026, missing the consensus estimate of -$1.20. The report was announced on Thursday, November 5, 2026. What was Zenas BioPharma's revenue for Q3 2026? Zenas BioPharma reported revenue of $10 million for Q3 2026. When is Zenas BioPharma's next earnings date? Zenas BioPharma's next earnings date is estimated for Wednesday, November 18, 2026. MarketBeat tracks confirmed and estimated earnings dates for Zenas BioPharma on the company's earnings history page. Zenas BioPharma Earnings HeadlinesZenas BioPharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update1 hour ago | globenewswire.comZenas BioPharma, Inc. (ZBIO) R&D Event: Obexelimab in SLE and ZB021 Development TranscriptOctober 27, 2026 | seekingalpha.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds, he licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 5 at 1:00 AM | Behind the Markets (Ad)Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 16, 2026 | globenewswire.comZenas BioPharma Highlights New Phase 3 Obexelimab DataOctober 14, 2026 | theglobeandmail.comZenas BioPharma (ZBIO) Is Down 5.1% After New Phase 3 Obexelimab IgG4-RD Data ReleaseOctober 13, 2026 | uk.finance.yahoo.comSee More Zenas BioPharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Zenas BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zenas BioPharma and other key companies, straight to your email. Email Address About Zenas BioPharmaZenas BioPharma (NASDAQ:ZBIO) is a clinical-stage biopharmaceutical company focused on developing immune-based therapies for autoimmune diseases and other serious immune-mediated conditions. The company’s research is centered on treatments designed to modulate B-cell activity and restore balance to the immune system. Zenas’ lead product candidate is obexelimab, an investigational bifunctional antibody designed to bind CD19 on B cells and Fc gamma receptor IIb. By engaging both targets, obexelimab is intended to inhibit pathogenic B-cell activity without broadly depleting B cells. The company is evaluating the therapy in conditions including IgG4-related disease and systemic lupus erythematosus, among other potential indications. The company was formed to advance therapies for diseases with significant unmet medical needs and conducts its clinical development activities through studies involving patients in the United States and other geographies. Zenas BioPharma became a publicly traded company on the Nasdaq under the symbol ZBIO in 2024.View Zenas BioPharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Keurig Dr Pepper's Beverage Growth Raises a Tough Question About Its Coffee SplitAmazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?Advanced Micro Devices' Q3 Results Answer a Big Question, But Another Remains3 Dividend Increases Above 10%, But Which Offers the Most Income?High Voltage Returns: Talen Energy Powers the Data Center RushBloom Energy: The Off-Grid Answer to AI's Power DrainWhy ExxonMobil and Chevron Reminded Investors to Keep it Simple Upcoming Earnings Enbridge (11/6/2026)Brookfield Asset Management (11/6/2026)Humana (11/6/2026)Moderna (11/6/2026)Occidental Petroleum (11/9/2026)KKR & Co. Inc. (11/9/2026)Barrick Mining (11/9/2026)Constellation Energy (11/9/2026)Petroleo Brasileiro S.A.- Petrobras (11/10/2026)Transdigm Group (11/10/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
